Home Intercept Pharmaceuticals

Intercept Pharmaceuticals

acquired
IPO Delisting
Biopharmaceutical Manufacturer
Basic
Enterprise Profile

Basic Information

Intercept Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. It provides a FXR modulator called INT-747, which can treat patients with chronic autoimmune liver disease. The company's drug development programs also focus on modulating bile acid receptors to improve metabolism and liver function in chronic liver diseases.
Intercept Pharmaceuticals, Inc.
NewJersey,United States of America
more than 500 people
January 01, 2002
info@interceptpharma.com

Enterprise Profile

Industrial Sector
New Drug Development Manufacture of Chemical Pharmaceutical Preparations
Technology
Biotechnology
Concept
Therapeutic Products
Application Scenarios
Chemical Drug Innovative Drugs Prescription Drug